Company: HCTI
Filing Date: 2025-02-18
Form Type: 10-K/A
Source: 0001213900-25-014503
Chunk: 75

Company: Healthcare Triangle, Inc.
Filing Date: 2025-02-18
Form: 10-K/A
Chunk 75
---
 2024, reported earlier as collected adjusted to accounts receivable. Corresponding impact given in short term borrowing. |

| (ii) | The Company recorded $435 as debt issuance cost for the 
 period ending December 31, 2023.                        |

| (iii) | Written off $3,115 to record loss due to impairment. |

| (iv) | The Company adopted ASU 2020-06 in financial year 2023                                                                                
 using the relative fair value method and recorded debt discount; and an allocation of $954 towards warrant was recorded as additional 
 paid-in capital using the relative fair value method.                                                                                 |

| (v) | Adjustment of additional general cost accrual of $124 |

| (vi) | Adjustment to record debt discount for the relative fair      
 value of warrants issued with convertible debt during FY 2023 |

| (vii) | Adjustment of $205 to remove unsupported debit balance                                                                                    
 included in liabilities, $356 relative fair value of warrant, $56 additional professional fees and $149 related to ESOP cost adjustments. |

| (viii) | There was an impact of $6,351 to retained earnings in                                                                  
 2023 from adjustments in 2022. Net P&L effect in 2023 went down by $3,655. Hence, the difference is the $2,697 change. |

F-9 HEALTHCARE TRIANGLE INC

Consolidated Statements of Operations

|                                                                                     |     | Impact of changes in estimates 
 As previously                  
 reported                       |           |   |     | Adjustments |         |   |     | As restated  
 December 31, 
 2023         |           |   |
|:------------------------------------------------------------------------------------|:----|:-------------------------------|----------:|:--|:----|:------------|--------:|:--|:----|:-------------|----------:|:--|
| Net revenue                                                                         |     | $                              |    33,203 |   |     | $           |       - |   |     | $            |    33,203 |   |
| Cost of revenue (exclusive of depreciation and amortization shown separately below) |     |                                |    26,426 |   |     |             |       - |   |     |              |    26,426 |   |
| Operating expenses                                                                  |     |                                |           |   |     |             |         |   |     |              |           |   |
| Research